ALDAGEN's senior management has extensive experience in pharmaceutical and biotechnology product and clinical development and commercialization, business development, and financings.
W. Thomas Amick, Chairman & Chief Executive Officer: Tom Amick has
Proven executive leadership abilities through a consistent string of successes during his 30 year career with Johnson & Johnson.
Formerly: President, Ortho Biotech Europe; President, Janssen-Ortho; Vice President, Oncology Franchise, Ortho Biotech. Tom was integrally responsible for building Johnson & Johnson's fastest growing, largest and most profitable biotechnology business to over $2.5 billion in annual revenues.
Currently serves on Board of Directors for four biotech companies and is an advisor to several venture capital firms.
Ed Field, President & Chief Operating Officer
17 years experience in growing and managing maturing biotech companies across multiple therapeutic areas
Past President/CEO of Molecumetics, Ltd. and Inologic, Inc.
Biotechnology venture investment experience with Tredegar Investments
Dave Carberry, Chief Financial Officer
27 years of senior level financial management experience at Johnson & Johnson
Experience in pharmaceuticals and medical device businesses as well as extensive M&A experience
Andrew Balber, PhD, Chief Scientific Officer
24 years of cell therapy experience in commercial and academic settings
Former Duke University faculty member in immunology and Director, Flow Cytometry Center, Duke Comprehensive Cancer Center
Subsequently Associate Director, Office of Science & Technology, Duke University, involved in numerous early development efforts with biologicals and cell therapies including Genzyme’s MyozymeR product and the establishment of Merix Bioscience, now Argos Therapeutics
Larry Keller, MD, Chief Medical Officer
Board certified pediatric cardiologist
Extensive drug development experience at Pfizer/Parke Davis, Kos/Abbott
